From Wikipedia, the free encyclopedia
American oncologist
Luis Alberto Diaz, Jr. is the Head of the Division of Solid Tumor
Oncology in
Memorial Sloan Kettering’s Department of Medicine.
[1]
Education and career
Diaz earned his undergraduate and medical degree at the
University of Michigan and
Michigan Medicine , respectively.
[2] He completed his residency in internal medicine and medical oncology fellowship at
Johns Hopkins School of Medicine .
[1]
[3] Diaz was a faculty member in the Department of Oncology at the Johns Hopkins University School of Medicine.
[4] He was also a member of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins, where he worked with colleagues
Bert Vogelstein ,
Kenneth Kinzler , Nickolas Papadopoulos,
Victor Velculescu and Shibin Zhou.
[4] He was also head of the
Swim Across America Laboratory at Johns Hopkins.
[4]
In 2017, Diaz became Head of the Solid Tumor Oncology division at Memorial Sloan Kettering. The same year, he was selected to lead the
Stand Up to Cancer “Dream Team” against
colorectal cancer .
[5] Diaz has founded several companies that focus on genomic analyses of cancers, including Inostics,
[6] PapGene,
[7] and Personal Genome Diagnostics. Diaz was named to the Board of Directors of Jounce Therapeutics in 2017.
[3]
Diaz was elected to the
National Academy of Medicine in 2023.
[8]
Research
Diaz researched the development of a
liquid biopsy that can be used to test for the presence of cancer and to monitor its response to therapy.
[9]
[10]
[11]
[12] Also while at Hopkins, he and his colleagues developed a
Pap smear to detect early-stage
ovarian and
endometrial cancers .
[13]
[14] He also led a study of
pembrolizumab to target
tumors that share a particular
biomarker called
mismatch repair deficiency .
[15]
[16]
[17] It was the first
FDA approval for a cancer treatment based on a biomarker rather than the location in the body where the tumor originated.
[15]
[18]
[19]
Awards
See also
References
^
a
b
"Memorial Sloan Kettering Cancer Center names head of solid tumor oncology" . 2017-04-26. Retrieved 2018-10-04 .
^
"Colorectal Cancer Vulnerabilities Dream Team - Stand Up to Cancer" . Stand Up to Cancer . Retrieved 2018-10-04 .
^
a
b
"Luis A. Diaz Jr. Executive Profile" . www.bloomberg.com . Retrieved 11 October 2018 .
^
a
b
c
"Luis A. Diaz, MD, Named Head of Solid Tumor Oncology at MSK - The ASCO Post" . www.ascopost.com .
American Society of Clinical Oncology . 2017-05-10. Retrieved 2018-10-04 .
^
"Diaz Named Solid Tumor Oncology Division Head at Memorial Sloan Kettering" . Targeted Oncology . 2017-05-04. Retrieved 2018-10-04 .
^
"Sysmex Inostics - Welcome - sysmex inostics" . www.sysmex-inostics.com . Retrieved 2019-02-03 .
^
"PapGene, Inc. | Advancing the early detection of curable cancers" . papgeneinc.com . Retrieved 2019-02-03 .
^
"National Academy of Medicine Elects 100 New Members" . National Academy of Medicine . 9 October 2023. Retrieved 9 October 2023 .
^ Regalado, Antonio (2014-08-11).
"New DNA Tests on Blood Can Catch Cancer Early" . MIT Technology Review . Retrieved 2018-10-04 .
^ Diehl, Frank; Schmidt, Kerstin; Choti, Michael A.; Romans, Katharine; Goodman, Steven; Li, Meng; Thornton, Katherine; Agrawal, Nishant; Sokoll, Lori (September 2008).
"Circulating mutant DNA to assess tumor dynamics" . Nature Medicine . 14 (9): 985–990.
doi :
10.1038/nm.1789 .
ISSN
1546-170X .
PMC
2820391 .
PMID
18670422 .
^ Diaz, Luis A.; Williams, Richard T.; Wu, Jian; Kinde, Isaac; Hecht, J. Randolph; Berlin, Jordan; Allen, Benjamin; Bozic, Ivana; Reiter, Johannes G. (2012-06-28).
"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers" . Nature . 486 (7404): 537–540.
Bibcode :
2012Natur.486..537D .
doi :
10.1038/nature11219 .
ISSN
1476-4687 .
PMC
3436069 .
PMID
22722843 .
^ Bettegowda, Chetan; Sausen, Mark; Leary, Rebecca J.; Kinde, Isaac; Wang, Yuxuan; Agrawal, Nishant; Bartlett, Bjarne R.; Wang, Hao; Luber, Brandon (2014-02-19).
"Detection of circulating tumor DNA in early- and late-stage human malignancies" . Science Translational Medicine . 6 (224): 224ra24.
doi :
10.1126/scitranslmed.3007094 .
ISSN
1946-6242 .
PMC
4017867 .
PMID
24553385 .
^ Grady, Denise (2013-01-09).
"Pap Test May Prove Useful at Detecting More Types of Cancer, Study Suggests" . New York Times . Retrieved 2018-10-04 .
^ Kinde, Isaac; Bettegowda, Chetan; Wang, Yuxuan; Wu, Jian; Agrawal, Nishant; Shih, Ie-Ming; Kurman, Robert; Dao, Fanny; Levine, Douglas A. (2013-01-09).
"Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers" . Science Translational Medicine . 5 (167): 167ra4.
doi :
10.1126/scitranslmed.3004952 .
ISSN
1946-6242 .
PMC
3757513 .
PMID
23303603 .
^
a
b McGinley, Laurie (2017-05-28).
" 'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope" . Washington Post . Retrieved 2018-10-04 .
^ Le, Dung T.; Durham, Jennifer N.; Smith, Kellie N.; Wang, Hao; Bartlett, Bjarne R.; Aulakh, Laveet K.; Lu, Steve; Kemberling, Holly; Wilt, Cara (28 July 2017).
"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade" . Science . 357 (6349): 409–413.
Bibcode :
2017Sci...357..409L .
doi :
10.1126/science.aan6733 .
ISSN
1095-9203 .
PMC
5576142 .
PMID
28596308 .
^ Le, Dung T.; Uram, Jennifer N.; Wang, Hao; Bartlett, Bjarne R.; Kemberling, Holly; Eyring, Aleksandra D.; Skora, Andrew D.; Luber, Brandon S.; Azad, Nilofer S. (2015-06-25).
"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency" . The New England Journal of Medicine . 372 (26): 2509–2520.
doi :
10.1056/NEJMoa1500596 .
ISSN
1533-4406 .
PMC
4481136 .
PMID
26028255 .
^ Kolata, Gina (2017-06-08).
"Cancer Drug Proves to Be Effective Against Multiple Tumors" . New York Times . Retrieved 2018-10-04 .
^ Commissioner, Office of the.
"Press Announcements - FDA approves first cancer treatment for any solid tumor with a specific genetic feature" . www.fda.gov . Retrieved 2019-02-03 .
^
a
b
c
"AACR Team Science Award" . www.aacr.org .
American Association for Cancer Research . Retrieved 2018-10-04 .
^
"The American Society for Clinical Investitagation" . Retrieved 2018-10-04 .
External links